VASO Corp 10-Q for FY2022 Q2
VASO Corp (VASO)
About this 10-Q
VASO Corp filed this 10-Q on August 15, 2022, covering the quarter ended June 30, 2022 (FY2022 Q2).
Headline figures
Quarter ended June 30, 2022, as reported in this filing, compared with the same period a year earlier where the filing states it.
- Revenue
- $19.5M
- up 20.9% from $16.13M a year earlier
- Net income
- $1.5M
- down 46.2% from net income of $2.78M a year earlier
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
For the quarterly period ended
For the transition period from _______________ to ______________
Commission File Number:
(Exact name of registrant as specified in its charter) |
| ||
(State or other jurisdiction of . incorporation or organization) | (IRS Employer Identification Number) |
(Address of principal executive offices) |
(
Registrant’s Telephone Number
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large Accelerated Filer | ☐ | Accelerated Filer | ☐ |
☒ | Smaller Reporting Company | ||
|
| Emerging Growth Company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
Securities registered pursuant to Section 12 (b) of the Act: None
Number of Shares Outstanding of Common Stock, $.001 Par Value, at August 12, 2022 –
Vaso Corporation and Subsidiaries
INDEX
| Page 2 |
| Table of Contents |
PART I – FINANCIAL INFORMATION
ITEM 1 - FINANCIAL STATEMENTS
Vaso Corporation and Subsidiaries
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
ASSETS |
|
|
|
|
|
| ||
CURRENT ASSETS |
|
|
|
|
|
| ||
Cash and cash equivalents |
| $ |
|
| $ |
| ||
Short-term investments |
|
|
|
|
|
| ||
Accounts and other receivables, net of an allowance for doubtful |
|
|
|
|
|
|
|
|
accounts and commission adjustments of $ |
|
|
|
|
|
|
|
|
and $ |
|
|
|
|
|
| ||
Receivables due from related parties |
|
|
|
|
|
| ||
Inventories |
|
|
|
|
|
| ||
Deferred commission expense |
|
|
|
|
|
| ||
Prepaid expenses and other current assets |
|
|
|
|
|
| ||
Total current assets |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Property and equipment, net of accumulated depreciation of |
|
|
|
|
|
|
|
|
$ |
|
|
|
|
|
| ||
Opearting lease right of use assets |
|
|
|
|
|
| ||
Goodwill |
|
|
|
|
|
| ||
Intangibles, net |
|
|
|
|
|
| ||
Other assets, net |
|
|
|
|
|
| ||
Investment in EECP Global |
|
|
|
|
|
| ||
Deferred tax assets, net |
|
|
|
|
|
| ||
Total assets |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
CURRENT LIABILITIES |
|
|
|
|
|
|
|
|
Accounts payable |
| $ |
|
| $ |
| ||
Accrued commissions |
|
|
|
|
|
| ||
Accrued expenses and other liabilities |
|
|
|
|
|
| ||
Finance lease liabilities - current |
|
|
|
|
|
| ||
Operating lease liabilities - current |
|
|
|
|
|
| ||
Sales tax payable |
|
|
|
|
|
| ||
Deferred revenue - current portion |
|
|
|
|
|
| ||
Notes payable - current portion |
|
|
|
|
|
| ||
Due to related party |
|
|
|
|
|
| ||
Total current liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
LONG-TERM LIABILITIES |
|
|
|
|
|
|
|
|
Notes payable, net of current portion |
|
|
|
|
|
| ||
Finance lease liabilities, net of current portion |
|
|
|
|
|
| ||
Operating lease liabilities, net of current portion |
|
|
|
|
|
| ||
Deferred revenue, net of current portion |
|
|
|
|
|
| ||
Other long-term liabilities |
|
|
|
|
|
| ||
Total long-term liabilities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
COMMITMENTS AND CONTINGENCIES (NOTE M) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
STOCKHOLDERS' EQUITY |
|
|
|
|
|
|
|
|
Preferred stock, $.01 par value; |
|
|
|
|
|
|
|
|
issued and outstanding at June 30, 2022 and December 31, 2021 |
|
|
|
|
|
| ||
Common stock, $.001 par value; |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
| |||
Additional paid-in capital |
|
|
|
|
|
| ||
Accumulated deficit |
|
| ( | ) |
|
| ( | ) |
Accumulated other comprehensive income |
|
| ( | ) |
|
|
| |
Treasury stock, at cost, |
|
| ( | ) |
|
| ( | ) |
Total stockholders’ equity |
|
|
|
|
|
| ||
|
| $ |
|
| $ |
| ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| Page 3 |
| Table of Contents |
Vaso Corporation and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME
(in thousands, except per share data)
|
| Three months ended |
|
| Six months ended |
| ||||||||||
|
| June 30, |
|
| June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
Revenues |
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
| ||||
Managed IT systems and services |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Professional sales services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Equipment sales and services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of managed IT systems and services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Cost of professional sales services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Cost of equipment sales and services |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Gross profit |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Research and development |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total operating expenses |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Operating income (loss) |
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other (expense) income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest and financing costs |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Interest and other income, net |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
| ||
Gain on forgiveness of PPP loan |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Loss on disposal of fixed assets |
|
|
|
|
|
|
|
| ( | ) |
|
|
| |||
Total other (expense) income, net |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Income tax (expense) benefit |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Net income |
|
|
|
|
|
|
|
|
|
|
|
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency translation gain (loss) |
|
| ( | ) |
|
|
|
|
| ( | ) |
|
|
| ||
Comprehensive income |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income per common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic and diluted |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average common shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
- basic |
|
|
|
|
|
|
|
|
|
|
|
| ||||
- diluted |
|
|
|
|
|
|
|
|
|
|
|
| ||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| Page 4 |
| Table of Contents |
Vaso Corporation and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY
(in thousands)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accumulated |
|
|
|
| ||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
| Additional |
|
|
|
|
| Other |
|
| Total |
| ||||||||
|
| Common Stock |
|
| Treasury Stock |
|
| Paid-in- |
|
| Accumulated |
|
| Comprehensive |
|
| Stockholders’ |
| ||||||||||||||
|
| Shares |
|
| Amount |
|
| Shares |
|
| Amount |
|
| Capital |
|
| Deficit |
|
| Loss |
|
| Equity |
| ||||||||
Balance at January 1, 2021 |
|
|
|
| $ |
|
|
| ( | ) |
|
| ( | ) |
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||
Share-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Foreign currency translation loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) | ||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balance at March 31, 2021 (unaudited) |
|
|
|
| $ |
|
|
| ( | ) |
| $ | ( | ) |
| $ |
|
| $ | ( | ) |
| $ | ( | ) |
| $ |
| ||||
Share-based compensation |
|
|
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |||||||
Foreign currency translation gain |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Net income |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Balance at June 30, 2021 (unaudited) |
|
|
|
| $ |
|
|
| ( | ) |
| $ | ( | ) |
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance at January 1, 2022 |
|
|
|
| $ |
|
|
| ( | ) |
|
| ( | ) |
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||
Share-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Foreign currency translation loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) | ||||
Net loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||||
Balance at March 31, 2022 (unaudited) |
|
|
|
| $ |
|
|
| ( | ) |
| $ | ( | ) |
| $ |
|
| $ | ( | ) |
| $ |
|
| $ |
| |||||
Share-based compensation |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Foreign currency translation loss |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
| ( | ) |
|
| ( | ) | ||||
Net income |
|
| - |
|
|
|
|
|
| - |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||
Balance at June 30, 2022 (unaudited) |
|
|
|
| $ |
|
|
| ( | ) |
| $ | ( | ) |
| $ |
|
| $ | ( | ) |
| $ | ( | ) |
| $ |
| ||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| Page 5 |
| Table of Contents |
Vaso Corporation and Subsidiaries
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
|
| Six months ended |
| |||||
|
| June 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
Cash flows from operating activities |
| (unaudited) |
|
| (unaudited) |
| ||
Net income |
| $ |
|
| $ |
| ||
Adjustments to reconcile net income to net |
|
|
|
|
|
|
|
|
cash (used in) provided by operating activities |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
| ||
(Gain) loss from investment in EECP Global |
|
|
|
|
|
| ||
Gain on forgiveness of PPP loan |
|
|
|
|
| ( | ) | |
Provision for doubtful accounts and commission adjustments |
|
|
|
|
|
| ||
Write-down of inventory |
|
|
|
|
|
| ||
Share-based compensation |
|
|
|
|
|
| ||
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
Accounts and other receivables |
|
|
|
|
|
| ||
Inventories |
|
| ( | ) |
|
|
| |
Deferred commission expense |
|
| ( | ) |
|
| ( | ) |
Prepaid expenses and other current assets |
|
|
|
|
|
| ||
Other assets, net |
|
| ( | ) |
|
| ( | ) |
Accounts payable |
|
| ( | ) |
|
| ( | ) |
Accrued commissions |
|
| ( | ) |
|
| ( | ) |
Accrued expenses and other liabilities |
|
| ( | ) |
|
|
| |
Sales tax payable |
|
|
|
|
| ( | ) | |
Deferred revenue |
|
|
|
|
|
| ||
Due to related party |
|
| ( | ) |
|
| ( | ) |
Other long-term liabilities |
|
|
|
|
|
| ||
Net cash provided by operating activities |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Cash flows from investing activities |
|
|
|
|
|
|
|
|
Purchases of equipment and software |
|
| ( | ) |
|
| ( | ) |
Redemption (purchases) of short-term investments |
|
|
|
|
|
| ||
Net cash (used in) provided by investing activities |
|
| ( | ) |
|
|
| |
|
|
|
|
|
|
|
|
|
Cash flows from financing activities |
|
|
|
|
|
|
|
|
Repayment on revolving lines of credit |
|
|
|
|
| ( | ) | |
Repayment of notes payable and finance lease obligations |
|
| ( | ) |
|
| ( | ) |
Net cash used in financing activities |
|
| ( | ) |
|
| ( | ) |
Effect of exchange rate differences on cash and cash equivalents |
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
NET INCREASE IN CASH AND CASH EQUIVALENTS |
|
|
|
|
|
| ||
Cash and cash equivalents - beginning of period |
|
|
|
|
|
| ||
Cash and cash equivalents - end of period |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL DISCLOSURE OF CASH INFORMATION |
|
|
|
|
|
|
|
|
Interest paid |
| $ |
|
| $ |
| ||
Income taxes paid |
| $ |
|
| $ |
| ||
|
|
|
|
|
|
|
|
|
SUPPLEMENTAL SCHEDULE OF NON-CASH INVESTING AND FINANCING ACTIVITIES |
|
|
|
|
|
|
|
|
Initial recognition of operating lease right of use asset and liability |
| $ |
|
| $ |
| ||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
| Page 6 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE A - ORGANIZATION AND PLAN OF OPERATIONS
Vaso Corporation was incorporated in Delaware in July 1987. Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries.
Overview
Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology (“IT”) industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
| · | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; |
|
|
|
| · | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for General Electric Healthcare (“GEHC”) into the healthcare provider middle market; and |
|
|
|
| · | Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices and software. |
VasoTechnology
VasoTechnology, Inc.was formed in May 2015, at the time the Company acquired all of the assets of NetWolves, LLC and its affiliates, including the membership interests in NetWolves Network Services, LLC (collectively, “NetWolves”). It currently consists of a managed network and security service division and a healthcare IT application division. Its current offerings include:
| · | Managed radiology and imaging applications (channel partner of select vendors of healthcare IT products). |
| · | Managed network infrastructure (routers, switches and other core equipment). |
| · | Managed network transport (FCC licensed carrier reselling over 175 facility partners). |
| · | Managed security services. |
VasoTechnology uses a combination of proprietary technology, methodology and third-party applications to deliver its value proposition.
VasoHealthcare
VasoHealthcare commenced operations in 2010, in conjunction with the Company’s execution of its exclusive sales representation agreement (“GEHC Agreement”) with GEHC, which is the healthcare business division of the General Electric Company (“GE”), to further the sale of certain healthcare capital equipment in the healthcare provider middle market. Sales of GEHC equipment by the Company have grown significantly since then.
VasoHealthcare’s current offerings consist of:
| · | GEHC diagnostic imaging capital equipment. |
| · | GEHC service agreements for the above equipment. |
| · | GEHC training services for use of the above equipment. |
| · | GEHC and third party financial services. |
| Page 7 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
VasoMedical
VasoMedical is the Company’s business division for its proprietary medical device operations, including the design, development, manufacturing, sales and service of various medical devices in the domestic and international markets and includes the Vasomedical Global and Vasomedical Solutions business units. These devices are primarily for cardiovascular monitoring and diagnostic systems. Its current offerings consist of:
| · | Biox™ series Holter monitors and ambulatory blood pressure recorders. |
| · | ARCS® series analysis, reporting and communication software for ECG and blood pressure signals. |
| · | MobiCare™ multi-parameter wireless vital-sign monitoring system. |
| · | EECP® therapy systems for non-invasive, outpatient treatment of ischemic heart disease. |
This segment uses its extensive cardiovascular device knowledge coupled with its significant engineering resources to cost-effectively create and market its proprietary technology. It works with a global distribution network of channel partners to sell its products. It also provides engineering and OEM services to other medical device companies.
NOTE B – INTERIM STATEMENT PRESENTATION
Basis of Presentation and Use of Estimates
The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") and pursuant to the accounting and disclosure rules and regulations of the Securities and Exchange Commission (the "SEC") for interim financial information. Certain information and disclosures normally included in the financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 31, 2022.
These unaudited condensed consolidated financial statements include the accounts of the companies over which we exercise control. In the opinion of management, the accompanying condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of interim results for the Company. The results of operations for any interim period are not necessarily indicative of results to be expected for any other interim period or the full year.
The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities as of the date of the condensed consolidated financial statements, the disclosure of contingent assets and liabilities in the unaudited condensed consolidated financial statements and the accompanying notes, and the reported amounts of revenues, expenses and cash flows during the periods presented. Actual amounts and results could differ from those estimates. The estimates and assumptions the Company makes are based on historical factors, current circumstances and the experience and judgment of the Company's management. The Company evaluates its estimates and assumptions on an ongoing basis.
Significant Accounting Policies and Recent Accounting Pronouncements
Recently Adopted Accounting Pronouncements
In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments, which provides new guidance regarding the measurement and recognition of credit impairment for certain financial assets. Such guidance will impact how we determine our allowance for estimated uncollectible receivables. In November 2019, the FASB issued ASU 2019-10, which changed the effective date of ASU 2016-13 for smaller reporting companies as defined by the SEC from first quarter of 2020 to the first quarter of 2023, with early adoption permitted. We are currently evaluating the effect that ASU 2016-13 will have on our consolidated financial statements and related disclosures.
| Page 8 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE C – REVENUE RECOGNITION
Disaggregation of Revenue
The following tables present revenues disaggregated by our business operations and timing of revenue recognition:
|
| (in thousands) |
| |||||||||||||||||||||||||||||
|
|
|
| |||||||||||||||||||||||||||||
|
| Three Months Ended June 30, 2022 (unaudited) |
|
| Three Months Ended June 30, 2021 (unaudited) |
| ||||||||||||||||||||||||||
|
|
|
|
| Professional |
|
|
|
|
|
|
|
|
|
| Professional |
|
|
|
|
|
| ||||||||||
|
| IT segment |
|
| sales service segment |
|
|
Equipment segment |
|
| Total |
|
| IT segment |
|
| sales service segment |
|
| Equipment segment |
|
| Total |
| ||||||||
Network services |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||||||
Software sales and support |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Commissions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Medical equipment sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Medical equipment service |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
|
| $ |
|
| $ |
|
| $ |
|
| $ | 19,502 |
|
| $ |
|
| $ |
|
| $ |
|
| $ | 16,131 |
| ||||||
|
| Six Months Ended June 30, 2022 (unaudited) |
|
| Six Months Ended June 30, 2021 (unaudited) |
| ||||||||||||||||||||||||||
|
|
|
| Professional sales |
|
|
|
|
|
|
|
| Professional sales |
|
|
|
|
| ||||||||||||||
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
| ||||||||
Network services |
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||||||
Software sales and support |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Commissions |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Medical equipment sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| ||||||||
Medical equipment service |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| 66 |
|
|
|
| |||||||
|
| $ |
|
| $ |
|
| $ |
|
| $ | 36,512 |
|
| $ |
|
| $ | 9,626 |
|
| $ | 1,329 |
|
| $ | 32,651 |
| ||||
|
| Three Months Ended June 30, 2022 (unaudited) |
|
| Three Months Ended June 30, 2021 (unaudited) |
| ||||||||||||||||||||||||||
|
|
|
|
| Professional sales |
|
|
|
|
|
|
|
|
|
| Professional sales |
|
|
|
|
|
| ||||||||||
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
| ||||||||
Revenue recognized over time |
| $ |
|
| $ | - |
|
| $ |
|
| $ | 9,159 |
|
| $ |
|
| $ | - |
|
| $ |
|
| $ | 9,277 |
| ||||
Revenue recognized at a point in time |
|
|
|
|
|
|
|
|
|
|
| 10,343 |
|
|
|
|
|
|
|
|
|
|
|
| 6,854 |
| ||||||
|
| $ | 10,019 |
|
| $ |
|
| $ | 629 |
|
| $ | 19,502 |
|
| $ | 10,442 |
|
| $ |
|
| $ | 718 |
|
| $ | 16,131 |
| ||
|
| Six Months Ended June 30, 2022 (unaudited) |
|
| Six Months Ended June 30, 2021 (unaudited) |
| ||||||||||||||||||||||||||
|
|
|
|
| Professional sales |
|
|
|
|
|
|
|
|
|
| Professional sales |
|
|
|
|
|
| ||||||||||
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
|
| IT segment |
|
| service segment |
|
| Equipment segment |
|
| Total |
| ||||||||
Revenue recognized over time |
| $ |
|
| $ | - |
|
| $ |
|
| $ | 18,457 |
|
| $ |
|
| $ |
|
| $ |
|
| $ | 19,334 |
| |||||
Revenue recognized at a point in time |
|
|
|
|
|
|
|
|
|
|
| 18,055 |
|
|
|
|
|
|
|
|
|
|
|
| 13,317 |
| ||||||
|
| $ | 20,022 |
|
| $ |
|
| $ | 1,029 |
|
| $ | 36,512 |
|
| $ | 21,696 |
|
| $ |
|
| $ |
|
| $ | 32,651 |
| |||
| Page 9 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
Transaction Price Allocated to Remaining Performance Obligations
As of June 30, 2022, the aggregate amount of transaction price allocated to performance obligations that are unsatisfied (or partially unsatisfied) for executed contracts approximates $
|
| (in thousands) |
| |||||||||||||
|
| Fiscal years of revenue recognition (unaudited) |
| |||||||||||||
|
| 2022 |
|
| 2023 |
|
| 2024 |
|
| Thereafter |
| ||||
Unfulfilled performance obligations |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Contract Liabilities
Contract liabilities arise in our healthcare IT, VasoHealthcare, and VasoMedical businesses. In our healthcare IT business, payment arrangements with clients typically include an initial payment due upon contract signing and milestone-based payments based upon product delivery and go-live, as well as post go-live monthly payments for subscription and support fees. Customer payments received, or receivables recorded, in advance of go-live and customer acceptance, where applicable, are deferred as contract liabilities. Such amounts aggregated approximately $
In our VasoHealthcare business, we bill amounts for certain milestones in advance of customer acceptance of the underlying equipment. Such amounts aggregated approximately $
In our VasoMedical business, we bill amounts for post-delivery services and varying duration service contracts in advance of performance. Such amounts aggregated approximately $
During the three and six months ended June 30, 2022, we recognized approximately $
NOTE D – SEGMENT REPORTING AND CONCENTRATIONS
Vaso Corporation principally operates in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three reportable segments.
| · | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; |
|
|
|
| · | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and |
|
|
|
| · | Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices. |
| Page 10 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
The chief operating decision maker is the Company’s Chief Executive Officer, who, in conjunction with upper management, evaluates segment performance based on operating income and adjusted EBITDA (net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash stock-based compensation). Administrative functions such as finance, human resources, and information technology are centralized and related expenses allocated to each segment. Other costs not directly attributable to operating segments, such as audit, legal, director fees, investor relations, and others, as well as certain assets – primarily cash balances – are reported in the Corporate entity below. There are no intersegment revenues. Summary financial information for the segments is set forth below:
|
| (in thousands) |
| |||||||||||||
|
| Three months ended June 30, |
|
| Six months ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
| ||||
Revenues from external customers |
|
|
|
|
|
|
|
|
|
|
|
| ||||
IT |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Professional sales service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Equipment |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total revenues |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IT |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Professional sales service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Equipment |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total gross profit |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IT |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
| $ | ( | ) |
Professional sales service |
|
|
|
|
| ( | ) |
|
|
|
|
| ( | ) | ||
Equipment |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Corporate |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Total operating income (loss) |
| $ |
|
| $ | ( | ) |
| $ |
|
| $ | ( | ) | ||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IT |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Professional sales service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Equipment |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Corporate |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total depreciation and amortization |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital expenditures |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
IT |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Professional sales service |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Equipment |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Corporate |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Total cash capital expenditures |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Identifiable Assets |
|
|
|
|
|
| ||
IT |
| $ |
|
| $ |
| ||
Professional sales service |
|
|
|
|
|
| ||
Equipment |
|
|
|
|
|
| ||
Corporate |
|
|
|
|
|
| ||
Total assets |
| $ |
|
| $ |
| ||
| Page 11 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
GE Healthcare accounted for
NOTE E –NET INCOME PER COMMON SHARE
Basic earnings per common share is computed as earnings applicable to common stockholders divided by the weighted-average number of common shares outstanding for the period. Diluted earnings per common share reflects the potential dilution that could occur if securities or other contracts to issue common shares were exercised or converted to common stock.
Diluted earnings per share were computed based on the weighted average number of shares outstanding plus all potentially dilutive common shares. A reconciliation of basic to diluted shares used in the earnings per share calculation is as follows:
|
| (in thousands) |
| |||||||||||||
|
| Three months ended June 30, |
|
| Six months ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
| ||||
Basic weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Dilutive effect of unvested restricted shares |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Diluted weighted average shares outstanding |
|
|
|
|
|
|
|
|
|
|
|
| ||||
The following table represents common stock equivalents that were excluded from the computation of diluted earnings per share for the three and six months ended June 30, 2022 and 2021, because the effect of their inclusion would be anti-dilutive.
|
| (in thousands) |
| |||||||||||||
|
| Three months ended June 30, |
|
| Six months ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
| ||||
Restricted common stock grants |
|
|
|
|
|
|
|
|
|
|
|
| ||||
NOTE F – ACCOUNTS AND OTHER RECEIVABLES, NET
The following table presents information regarding the Company’s accounts and other receivables as of June 30, 2022 and December 31, 2021:
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Trade receivables |
| $ |
|
| $ |
| ||
Unbilled receivables |
|
|
|
|
|
| ||
Allowance for doubtful accounts and commission adjustments |
|
| ( | ) |
|
| ( | ) |
Accounts and other receivables, net |
| $ |
|
| $ |
| ||
Contract receivables under Topic 606 consist of trade receivables and unbilled receivables. Trade receivables include amounts due for shipped products and services rendered. Unbilled receivables represent variable consideration recognized in accordance with Topic 606 but not yet billable. Amounts recorded – billed and unbilled - under the GEHC Agreement are subject to adjustment in subsequent periods should the underlying sales order amount, upon which the receivable is based, change.
| Page 12 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
Allowance for doubtful accounts and commission adjustments include estimated losses resulting from the inability of our customers to make required payments, and adjustments arising from subsequent changes in sales order amounts that may reduce the amount the Company will ultimately receive under the GEHC Agreement. Due from employees is primarily commission advances made to sales personnel.
NOTE G – INVENTORIES, NET
Inventories, net of reserves, consist of the following:
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Raw materials |
| $ |
|
| $ |
| ||
Work in process |
|
|
|
|
|
| ||
Finished goods |
|
|
|
|
|
| ||
|
| $ |
|
| $ |
| ||
The Company maintained reserves for slow moving inventories of $
NOTE H – GOODWILL AND OTHER INTANGIBLES
Goodwill of $
|
| (in thousands) |
| |||||
|
| Six months ended |
|
| Year ended |
| ||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Beginning of period |
| $ |
|
| $ |
| ||
Foreign currency translation adjustment |
|
| ( | ) |
|
|
| |
End of period |
| $ |
|
| $ |
| ||
| Page 13 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
The Company’s other intangible assets consist of capitalized customer-related intangibles, patent and technology costs, and software costs, as set forth in the following:
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
| |||
Customer-related |
|
|
|
|
|
| ||
Costs |
| $ |
|
| $ |
| ||
Accumulated amortization |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Patents and Technology |
|
|
|
|
|
|
|
|
Costs |
|
|
|
|
|
| ||
Accumulated amortization |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
Software |
|
|
|
|
|
|
|
|
Costs |
|
|
|
|
|
| ||
Accumulated amortization |
|
| ( | ) |
|
| ( | ) |
|
|
|
|
|
|
| ||
|
|
|
|
|
|
|
|
|
|
| $ |
|
| $ |
| ||
Patents and technology are amortized on a straight-line basis over their estimated useful lives of ten and eight years, respectively. The cost of significant customer-related intangibles is amortized in proportion to estimated total related revenue; cost of other customer-related intangible assets is amortized on a straight-line basis over the asset's estimated economic life of seven years. Software costs are amortized on a straight-line basis over its expected useful life of five years.
Amortization expense amounted to $
Amortization of intangibles for the next five years is:
|
| (in thousands) |
| |
Years ending December 31, |
| (unaudited) |
| |
Remainder of 2022 |
| $ |
| |
2023 |
|
|
| |
2024 |
|
|
| |
2025 |
|
|
| |
2026 |
|
|
| |
|
| $ |
| |
| Page 14 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE I – OTHER ASSETS, NET
Other assets, net consist of the following at June 30, 2022 and December 31, 2021:
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
| |||
Deferred commission expense - noncurrent |
| $ |
|
| $ |
| ||
Trade receivables - noncurrent |
|
|
|
|
|
| ||
Other, net of allowance for loss on loan receivable of $412 at June 30, 2022 and December 31, 2021 |
|
|
|
|
|
| ||
|
| $ |
|
| $ |
| ||
NOTE J – ACCRUED EXPENSES AND OTHER LIABILITIES
Accrued expenses and other liabilities consist of the following at June 30, 2022 and December 31, 2021:
|
| (in thousands) |
| |||||
|
| June 30, 2022 |
|
| December 31, 2021 |
| ||
|
| (unaudited) |
|
|
|
| ||
Accrued compensation |
| $ |
|
| $ |
| ||
Accrued expenses - other |
|
|
|
|
|
| ||
Other liabilities |
|
|
|
|
|
| ||
|
| $ |
|
| $ |
| ||
| Page 15 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE K - DEFERRED REVENUE
The changes in the Company’s deferred revenues are as follows:
|
| (in thousands) |
| |||||||||||||
|
| Three months ended June 30, |
|
| Six months ended June 30, |
| ||||||||||
|
| 2022 |
|
| 2021 |
|
| 2022 |
|
| 2021 |
| ||||
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
|
| (unaudited) |
| ||||
Deferred revenue at beginning of period |
| $ |
|
| $ |
|
| $ |
|
| $ |
| ||||
Net additions: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred extended service contracts |
|
|
|
|
|
|
|
|
|
|
| ( | ) | |||
Deferred commission revenues |
|
|
|
|
|
|
|
|
|
|
|
| ||||
Recognized as revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred extended service contracts |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Deferred commission revenues |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
|
| ( | ) |
Deferred revenue at end of period |
|
| 27,097 |
|
|
|
|
|
|
|
|
| 19,667 |
| ||
Less: current portion |
|
|
|
|
|
|
|
| 18,583 |
|
|
| 12,613 |
| ||
Long-term deferred revenue at end of period |
| $ |
|
| $ |
|
| $ | 8,514 |
|
| $ | 7,054 |
| ||
NOTE L – RELATED-PARTY TRANSACTIONS
The Company recorded interest charges aggregating approximately $
David Lieberman, the Vice Chairman of the Company’s Board of Directors, is a practicing attorney in the State of New York and a senior partner at the law firm of Beckman Lieberman & Associates LLP, which performs certain legal services for the Company. Fees of approximately $
The Company uses the equity method to account for its interest in EECP Global as it has the ability to exercise significant influence over the entity and reports its share of EECP Global operations in Other Income (Expense) on its condensed consolidated statements of operations. For the three months ended June 30, 2022 and 2021, the Company’s share of EECP Global’s loss was approximately $
| Page 16 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Notes to Condensed Consolidated Financial Statements (unaudited)
NOTE M – COMMITMENTS AND CONTINGENCIES
Litigation
The Company is currently, and has been in the past, a party to various legal proceedings, primarily employee related matters, incident to its business. The Company believes that the outcome of all pending legal proceedings in the aggregate is unlikely to have a material adverse effect on the business or consolidated financial condition of the Company.
Sales Representation Agreement
In October 2021, the Company concluded an amendment of the GEHC Agreement with GEHC, originally signed on May 19, 2010 and previously extended in 2012, 2015 and 2017. The amendment further extended the term of the agreement through December 31, 2026. Under the agreement, VasoHealthcare is the exclusive representative for the sale of select GE Healthcare diagnostic imaging products to certain customer segments/accounts in the
Employment Agreements
On May 10, 2019, the Company modified its Employment Agreement with its President and Chief Executive Officer, Dr. Jun Ma, to provide for a five-year term with extensions, unless earlier terminated by the Company, but in no event can it extend beyond May 31, 2026. The Employment Agreement provides for annual compensation of $
Operating Leases
The Company executed amendments to its facility leases in New York and Florida in March 2022 and June 2022, respectively. for three additional years in New York and two additional years in Florida, with rates increasing
| Page 17 |
| Table of Contents |
Vaso Corporation and Subsidiaries
ITEM 2 - MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Except for historical information contained in this report, the matters discussed are forward-looking statements that involve risks and uncertainties. When used in this report, words such as “anticipates”, “believes”, “could”, “estimates”, “expects”, “may”, “plans”, “potential” and “intends” and similar expressions, as they relate to the Company or its management, identify forward-looking statements. Such forward-looking statements are based on the beliefs of the Company’s management, as well as assumptions made by and information currently available to the Company’s management. Among the factors that could cause actual results to differ materially are the following: the effect of business and economic conditions, including the current COVID-19 pandemic which has already adversely affected operating results; the effect of the dramatic changes taking place in IT and healthcare; the impact of competitive procedures and products and their pricing; medical insurance reimbursement policies; unexpected manufacturing or supplier problems; unforeseen difficulties and delays in product development programs; the actions of regulatory authorities and third-party payers in the United States and overseas; continuation of the GEHC agreement and the risk factors reported from time to time in the Company’s SEC reports, including its recent report on Form 10-K. The Company undertakes no obligation to update forward-looking statements as a result of future events or developments.
Unless the context requires otherwise, all references to “we”, “our”, “us”, “Company”, “registrant”, “Vaso” or “management” refer to Vaso Corporation and its subsidiaries
General Overview
COVID-19 Pandemic
The COVID-19 pandemic has had and will continue to have a significant impact on the economy of the United States and the world, and it is anticipated that its negative impact to the Company’s financial condition and results of operations will continue. At this time, we cannot reasonably estimate what the total impact may be. The pandemic has resulted in workforce and travel restrictions and created business disruptions in supply chain, production and demand across many business sectors. For Vaso Corporation, we believe that significant uncertainty will continue to remain in all our businesses for the remainder of 2022 and beyond.
We have taken significant steps in our efforts to protect our workforce and our clients. Many of our employees have been working remotely and we are implementing plans to reopen our work sites consistent with the guidelines promulgated by the CDC and respective state governments. In addition, the Company received a $3.6 million loan under the Paycheck Protection Program of the CARES Act. This loan was used to principally cover our payroll costs for a period of time as specified by the rules, thereby allowing us to maintain our workforce and continue to provide services and solutions to our clients. In June 2021, the loan, as well as accrued interest, was forgiven in its entirety by the Small Business Administration.
Our Business Segments
Vaso Corporation (“Vaso”) was incorporated in Delaware in July 1987. We principally operate in three distinct business segments in the healthcare and information technology industries. We manage and evaluate our operations, and report our financial results, through these three business segments.
| · | IT segment, operating through a wholly-owned subsidiary VasoTechnology, Inc., primarily focuses on healthcare IT and managed network technology services; |
|
|
|
| · | Professional sales service segment, operating through a wholly-owned subsidiary Vaso Diagnostics, Inc. d/b/a VasoHealthcare, primarily focuses on the sale of healthcare capital equipment for GEHC into the healthcare provider middle market; and |
|
|
|
| · | Equipment segment, operating through a wholly-owned subsidiary VasoMedical, Inc., primarily focuses on the design, manufacture, sale and service of proprietary medical devices. |
| Page 18 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based upon the accompanying unaudited condensed consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). The preparation of financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, expenses, and the related disclosures at the date of the financial statements and during the reporting period. Although these estimates are based on our knowledge of current events, our actual amounts and results could differ from those estimates. The estimates made are based on historical factors, current circumstances, and the experience and judgment of our management, who continually evaluate the judgments, estimates and assumptions and may employ outside experts to assist in the evaluations.
Certain of our accounting policies are deemed “critical”, as they are both most important to the financial statement presentation and require management’s most difficult, subjective or complex judgments as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a discussion of our critical accounting policies, see Note B to the condensed consolidated financial statements and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC on March 31, 2022.
Results of Operations – For the Three Months Ended June 30, 2022 and 2021
Revenues
Total revenue for the three months ended June 30, 2022 and 2021 was $19,502,000 and $16,131,000, respectively, representing an increase of $3,371,000, or 21% year-over-year. On a segment basis, revenue in the professional sales services segment increased $3,883,000 while revenue in the IT and equipment segments decreased $423,000 and $89,000, respectively.
Revenue in the IT segment for the three months ended June 30, 2022 was $10,019,000 compared to $10,442,000 for the three months ended June 30, 2021, a decrease of $423,000, or 4%, of which $481,000 resulted from lower NetWolves revenues, partially offset by $58,000 higher revenues in the healthcare IT business. Our monthly recurring revenue in the IT segment accounted for $9,075,000 or 91% of the segment revenue in the second quarter of 2022, and $9,246,000 or 89% of the segment revenue for the same quarter last year (see Note C).
Commission revenues in the professional sales service segment were $8,854,000 in the second quarter of 2022, an increase of $3,883,000, or 78%, as compared to $4,971,000 in the same quarter of 2021. The increase in commission revenues was due primarily to both an increase in the volume of underlying equipment delivered by GEHC during the period and a higher blended commission rate applicable to such deliveries. The Company only recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of June 30, 2022, $27,090,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $8,511,000 was long-term. As of June 30, 2021, $19,655,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,046,000 was long-term. The increase in deferred revenue is principally due to an increase in new orders booked.
Revenue in the equipment segment decreased by $89,000, or 12%, to $629,000 for the three-month period ended June 30, 2022 from $718,000 for the same period of the prior year, principally due to lower equipment revenues in China as impacted by the COVID-19 lockdown.
Gross Profit
Gross profit for the three months ended June 30, 2022 and 2021 was $11,336,000, or 58% of revenue, and $8,640,000, or 54% of revenue, respectively, representing an increase of $2,696,000, or 31% year-over-year. On a segment basis, gross profit in the professional sales service segment increased $3,204,000, or 81%, while gross profit in the IT and equipment segments decreased $417,000, or 10%; and $91,000, or 16%, respectively.
| Page 19 |
| Table of Contents |
Vaso Corporation and Subsidiaries
IT segment gross profit for the three months ended June 30, 2022 was $3,677,000, or 37% of the segment revenue, compared to $4,094,000, or 39% of the segment revenue for the three months ended June 30, 2021. The year-over-year decrease of $417,000, or 10%, was primarily a result of lower sales volume in the NetWolves business, partially offset by higher sales volume and higher margin sales mix in the healthcare IT business.
Professional sales service segment gross profit was $7,180,000, or 81% of segment revenue, for the three months ended June 30, 2022 as compared to $3,976,000, or 80% of the segment revenue, for the three months ended June 30, 2021, reflecting an increase of $3,204,000, or 81%. The increase in absolute dollars was primarily due to higher commission revenue as a result of a higher blended commission rate and higher volume of GEHC equipment delivered during the second quarter of 2022 than in the same period last year. Cost of commissions in the professional sales service segment of $1,674,000 and $995,000, for the three months ended June 30, 2022 and 2021, respectively, reflected commission expense associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.
Equipment segment gross profit decreased to $479,000, or 76% of segment revenues, for the second quarter of 2022 compared to $570,000, or 79% of segment revenues, for the same quarter of 2021. The $91,000, or 16%, decrease in gross profit was the result of lower equipment revenue during the quarter compounded with higher material and labor costs.
Operating Income (Loss)
Operating income (loss) for the three months ended June 30, 2022 and 2021 was $1,562,000 and $(722,000), respectively, representing an increase of $2,284,000, due primarily to the increase in gross profit. On a segment basis, the IT segment recorded an operating loss of $918,000 in the second quarter of 2022 as compared to an operating loss of $246,000 in the same period of 2021; the equipment segment recorded an operating loss of $77,000 in the second quarter of 2022 as compared to an operating loss of $128,000 in the same period of 2021; and the professional sales service segment recorded operating income of $2,754,000 in the second quarter of 2022 as opposed to an operating loss of $47,000 in the same period of 2021.
Operating loss in the IT segment increased to $918,000 for the three-month period ended June 30, 2022 as compared to an operating loss of $246,000 in the same period of 2021, due to lower gross profit and higher selling, general, and administrative (“SG&A”) costs. Operating income in the professional sales service segment increased by $2,801,000 to $2,754,000 in the three-month period ended June 30, 2022 as compared to a $47,000 operating loss in the same period of 2021, due to higher gross profit partially offset by higher SG&A costs. The equipment segment reported an operating loss of $77,000 in the second quarter of 2022, compared to an operating loss of $128,000 in the second quarter 2021, an improvement of $51,000. The decrease in operating loss was due to lower SG&A and R&D costs partially offset by lower gross profit.
SG&A costs for the three months ended June 30, 2022 and 2021 were $9,604,000 and $9,192,000, respectively, representing an increase of $412,000, or 5% year-over-year. On a segment basis, SG&A costs in the IT segment increased by $257,000 in the second quarter of 2022 from the same quarter of the prior year due to higher personnel costs; SG&A costs in the professional sales service segment increased $403,000 due mainly to higher travel and personnel costs; and SG&A costs in the equipment segment decreased $142,000 due mainly to lower marketing and personnel costs. Corporate costs not allocated to segments decreased $106,000 due mainly to lower accounting and director fees.
Research and development (“R&D”) expenses were $170,000, or 1% of revenues, for the second quarters of both 2021 and 2022.
| Page 20 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
A reconciliation of net income to Adjusted EBITDA is set forth below:
|
| (in thousands) |
| |||||
|
| Three months ended June 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
|
| (unaudited) |
|
| (unaudited) |
| ||
Net income |
| $ | 1,495 |
|
| $ | 2,780 |
|
Interest expense (income), net |
|
| 5 |
|
|
| 78 |
|
Income tax expense |
|
| 18 |
|
|
| 50 |
|
Depreciation and amortization |
|
| 805 |
|
|
| 528 |
|
Share-based compensation |
|
| 6 |
|
|
| 8 |
|
Adjusted EBITDA |
| $ | 2,329 |
|
| $ | 3,444 |
|
Adjusted EBITDA decreased by $1,115,000, to $2,329,000 in the quarter ended June 30, 2022 from $3,444,000 in the quarter ended June 30, 2021. The decrease was attributable mainly to the decrease in net income arising from the non-recurring $3,646,000 gain on forgiveness of the PPP loan and interest in the second quarter of 2021, partially offset by the increase in depreciation and amortization.
Interest and Other Income (Expense)
Interest and other income (expense) for the three months ended June 30, 2022 was $(49,000) as compared to $3,552,000 for the corresponding period of 2021. The decrease in interest and other income (expense) was due primarily to the non-recurring $3,646,000 gain on forgiveness of the PPP loan and interest in the three months ended June 30, 2021.
Income Tax Expense
For the three months ended June 30, 2022, we recorded income tax expense of $18,000 as compared to $50,000 for the corresponding period of 2021. The $32,000 decrease arose mainly from lower tax expense in our China operations.
Net Income
Net income for the three months ended June 30, 2022 was $1,495,000 as compared to net income of $2,780,000 for the three months ended June 30, 2021, representing a decrease of $1,285,000. Income per share of $0.01 and $0.02 was recorded in the three-month periods ended June 30, 2022 and 2021, respectively. The principal cause of the decrease in net income is because the Company recorded the PPP loan forgiveness in the three months ended June 30, 2021, partially offset by higher operating income in the current year quarter.
| Page 21 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Results of Operations – For the Six Months Ended June 30, 2022 and 2021
Revenues
Total revenue for the six months ended June 30, 2022 and 2021 was $36,512,000 and $32,651,000, respectively, representing an increase of $3,861,000, or 12% year-over-year. On a segment basis, revenue in the professional sales service segment increased $5,835,000 while revenue in the IT and equipment segments decreased $1,674,000 and $300,000, respectively.
Revenue in the IT segment for the six months ended June 30, 2022 was $20,022,000 compared to $21,696,000 for the six months ended June 30, 2021, a decrease of $1,674,000, or 8%, of which $1,572,000 resulted from lower NetWolves revenue and $102,000 from lower healthcare IT revenue. Our monthly recurring revenue in the IT segment accounted for $18,309,000 or 91% of the segment revenue in the first half of 2022, and $19,271,000 or 89% of the segment revenue for the same period last year (see Note C).
Commission revenues in the professional sales service segment were $15,461,000 in the first half of 2022, an increase of $5,835,000, or 61%, as compared to $9,626,000 in the first half of 2021. The increase in commission revenues was due primarily to both an increase in the volume of underlying equipment delivered by GEHC during the period and a higher blended commission rate applicable to such deliveries. The Company recognizes commission revenue when the underlying equipment has been accepted at the customer site in accordance with the specific terms of the sales agreement. Consequently, amounts billable, or billed and received, under the agreement with GE Healthcare prior to customer acceptance of the equipment are recorded as deferred revenue in the condensed consolidated balance sheet. As of June 30, 2022, $27,090,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $8,511,000 was long-term. As of June 30, 2021, $19,655,000 in deferred commission revenue was recorded in the Company’s condensed consolidated balance sheet, of which $7,046,000 was long-term. The increase in deferred revenue is principally due to an increase in new orders booked.
Revenue in the equipment segment decreased by $300,000, or 23%, to $1,029,000 for the six-month period ended June 30, 2022 from $1,329,000 for the same period of the prior year, principally due to lower equipment deliveries in our China operations.
Gross Profit
Gross profit for the six months ended June 30, 2022 and 2021 was $21,105,000, or 58% of revenue, and $17,200,000, or 53% of revenue, respectively, representing an increase of $3,905,000, or 23% year-over-year. On a segment basis, gross profit in the professional sales service increased $4,845,000, or 63%, while gross profit in the IT and equipment segments decreased $690,000, or 8%, and $250,000, or 24%, respectively.
IT segment gross profit for the six months ended June 30, 2022 was $7,811,000, or 39% of the segment revenue, compared to $8,501,000, or 39% of the segment revenue for the six months ended June 30, 2021. The year-over-year decrease of $690,000, or 8%, was primarily a result of lower revenues at NetWolves, partially offset by higher margin sales mix in the healthcare IT business.
Professional sales service segment gross profit was $12,486,000, or 81% of segment revenue, for the six months ended June 30, 2022 as compared to $7,641,000, or 79% of the segment revenue, for the six months ended June 30, 2021, reflecting an increase of $4,845,000, or 63%. The increase in absolute dollars was primarily due to higher commission revenue as a result of a higher blended commission rate and higher volume of GEHC equipment delivered during the first half of 2022 than in the same period last year. Cost of commissions in the professional sales service segment of $2,975,000 and $1,985,000, for the six months ended June 30, 2022 and 2021, respectively, reflected commission expense associated with recognized commission revenues.
Commission expense associated with short-term deferred revenue is recorded as short-term deferred commission expense, or with long-term deferred revenue as part of other assets, on the balance sheet until the related commission revenue is recognized.
Equipment segment gross profit decreased to $808,000, or 79% of segment revenues, for the first half of 2022 compared to $1,058,000, or 80% of segment revenues, for the same half of 2021. The $250,000, or 24%, decrease in gross profit was primarily the result of a decrease in equipment sales and an increase in material and labor costs in our China operations during the first half of 2022.
| Page 22 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Operating Income (Loss)
Operating income (loss) for the six months ended June 30, 2022 and 2021 was $1,207,000 and $(1,262,000), respectively, representing an improvement of $2,469,000, due primarily to higher gross profit, partially offset by higher SG&A costs. On a segment basis, the IT segment recorded an operating loss of $1,057,000 in the first half of 2022 as compared to an operating loss of $179,000 in the same period of 2021; the professional sales service segment recorded operating income of $2,990,000 in the first half of 2022 as compared to an operating loss of $382,000 in the same period of 2021; and the equipment segment recorded an operating loss of $156,000 in the first half of 2022 as compared to an operating loss of $115,000 in the same period of 2021 .
Operating loss in the IT segment increased to $1,057,000 for the six-month period ended June 30, 2022 as compared to an operating loss of $179,000 in the same period of 2021, due to lower gross profit and higher selling, general, and administrative (“SG&A”) costs. The professional sales service segment reported operating income of $2,990,00 in the first half of 2022, an increase of $3,372,000 from an operating loss of $382,000 in the six-month period ended June 30, 2021, due to higher gross profit partially offset by higher SG&A costs. The equipment segment reported an operating loss of $156,000 in the first half of 2022, compared to an operating loss of $115,000 in the first half 2021, an increase of $41,000 due to lower gross profit, partially offset offset by lower SG&A costs.
SG&A costs for the six months ended June 30, 2022 and 2021 were $19,606,000 and $18,148,000, respectively, representing an increase of $1,458,000, or 8% year-over-year. On a segment basis, SG&A costs in the IT segment increased by $243,000 in the first half of 2022 from the same half of the prior year due to higher personnel costs; SG&A costs in the professional sales service segment increased by $1,472,000 due to higher travel and personnel costs; and SG&A costs in the equipment segment decreased by $240,000 due mainly to lower personnel costs. Corporate costs not allocated to segments decreased $17,000 due mainly to lower accounting and director fees.
Research and development (“R&D”) expenses were $292,000, or 1% of revenues, for the first half of 2022, a decrease of $22,000, or 7%, from $314,000, or 1% of revenues, for the first half of 2021. The decrease is primarily attributable to lower product development expenses in the IT segment.
Adjusted EBITDA
We define Adjusted EBITDA (earnings (loss) before interest, taxes, depreciation and amortization), which is a non-GAAP financial measure, as net income (loss), plus interest expense (income), net; tax expense; depreciation and amortization; and non-cash expenses for share-based compensation. Adjusted EBITDA is a metric that is used by the investment community for comparative and valuation purposes. We disclose this metric in order to support and facilitate the dialogue with research analysts and investors.
Adjusted EBITDA is not a measure of financial performance under U.S. GAAP and should not be considered a substitute for operating income, which we consider to be the most directly comparable U.S. GAAP measure. Adjusted EBITDA has limitations as an analytical tool, and when assessing our operating performance, you should not consider Adjusted EBITDA in isolation, or as a substitute for net income or other consolidated income statement data prepared in accordance with U.S. GAAP. Other companies may calculate Adjusted EBITDA differently than we do, limiting its usefulness as a comparative measure.
| Page 23 |
| Table of Contents |
Vaso Corporation and Subsidiaries
A reconciliation of net income to Adjusted EBITDA is set forth below:
|
| (in thousands) |
| |||||
|
| Six months ended June 30, |
| |||||
|
| 2022 |
|
| 2021 |
| ||
|
| (unaudited) |
|
| (unaudited) |
| ||
Net income |
| $ | 1,151 |
|
| $ | 2,137 |
|
Interest expense (income), net |
|
| 24 |
|
|
| 199 |
|
Income tax expense |
|
| 30 |
|
|
| 68 |
|
Depreciation and amortization |
|
| 1,258 |
|
|
| 1,124 |
|
Share-based compensation |
|
| 13 |
|
|
| 17 |
|
Adjusted EBITDA |
| $ | 2,476 |
|
| $ | 3,545 |
|
Adjusted EBITDA decreased by $1,069,000 to $2,476,000 in the period ended June 30, 2022 from $3,545,000 in the period ended June 30, 2021. The decrease was primarily attributable to the $3,646,000 non-recurring gain on PPP loan and interest forgiveness in the six months ended June 30, 2021, partially offset by higher depreciation and amortization.
Interest and Other Income (Expense)
Interest and other income (expense) for the six months ended June 30, 2022 was $(26,000) as compared to $3,467,000 for the corresponding period of 2021. The decrease in interest and other income was due primarily to the PPP loan and interest forgiveness in the six months ended June 30, 2021.
Income Tax Expense
We recorded income tax expense of $30,000 and $68,000 for the six-month periods ended June 30, 2022 and 2021, respectively. The decrease arose mainly from lower tax expense in our China operations.
Net Income
Net income for the six months ended June 30, 2022 was $1,151,000 as compared to net income of $2,137,000 for the six months ended June 30, 2021, representing a decrease of $986,000, or 46%. Income per share of $0.01 was recorded in the six-month periods ended June 30, 2022 and 2021, respectively. The principal cause of the decrease in net income is the PPP loan forgiveness in the six months ended June 30, 2021, partially offset by higher operating results in the six months ended June 30, 2022.
Liquidity and Capital Resources
Cash and Cash Flow
We have financed our operations from working capital. At June 30, 2022, we had cash and cash equivalents of $15,436,000 and negative working capital of $1,483,000, compared to cash and cash equivalents of $6,025,000 and negative working capital of $3,197,000 at December 31, 2021. $15,007,000 in negative working capital at June 30, 2022 is attributable to the net balance of deferred commission expense and deferred revenue. These are non-cash expense and revenue items and have no impact on future cash flows.
| Page 24 |
| Table of Contents |
Vaso Corporation and Subsidiaries
Cash provided by operating activities was $9,731,000, which consisted of net income after adjustments to reconcile net income to net cash of $2,634,000 and cash provided by operating assets and liabilities of $7,097,000, during the six months ended June 30, 2022, compared to cash provided by operating activities of $5,593,000 for the same period in 2021. The changes in the account balances primarily reflect a decrease in accounts and other receivables of $8,376,000 and an increase in deferred revenue of $2,132,000, partially offset by decreases in accrued commissions, accrued expenses, and accounts payable of $1,040,000, $941,000 and $628,000, respectively.
Cash used in investing activities during the six-month period ended June 30, 2022 was $204,000 attributed to $358,000 used for the purchase of equipment and software, offset by the redemption of $154,000 in short-term investments.
Cash used in financing activities during the six-month period ended June 30, 2022 was $125,000 for the repayment of notes payable and finance lease obligations.
Liquidity
The Company expects to generate sufficient cash flow from operations to satisfy its obligations for at least the next twelve months.
It is anticipated that the COVID-19 pandemic may continue to adversely impact our operations during and beyond the remaining quarters of 2022, depending on the duration of the pandemic and the timing and success of the continued reopening of the economy.
| Page 25 |
| Table of Contents |
Vaso Corporation and Subsidiaries
ITEM 4 - CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Disclosure controls and procedures reporting as promulgated under the Exchange Act is defined as controls and procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms. Disclosure controls and procedures include without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer (“CEO”) and Chief Financial Officer (“CFO”), or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.
Our CEO and our CFO have evaluated the effectiveness of the design and operation of our disclosure controls and procedures as of June 30, 2022 and have concluded that the Company’s disclosure controls and procedures were effective as of June 30, 2022.
Changes in Internal Control Over Financial Reporting
There were no changes in the Company’s internal control over financial reporting during the Company’s fiscal quarter ended June 30, 2022 that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
| Page 26 |
| Table of Contents |
Vaso Corporation and Subsidiaries
PART II - OTHER INFORMATION
ITEM 6 – EXHIBITS
Exhibits
|
|
| Page 27 |
| Table of Contents |
Vaso Corporation and Subsidiaries
In accordance with the requirements of the Exchange Act, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
VASO CORPORATION | |||
| By: | /s/ Jun Ma | ||
|
| Jun Ma | |
President and Chief Executive Officer | |||
| (Principal Executive Officer) | |||
|
|
|
|
|
| /s/ Michael J. Beecher. |
|
|
| Michael J. Beecher |
|
|
| Chief Financial Officer and Principal Accounting Officer |
|
Date: August 15, 2022
| Page 28 |
EXHIBIT 31.1
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Jun Ma, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Vaso Corporation and subsidiaries (the “registrant”); |
|
|
|
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions): |
|
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and |
|
|
|
|
|
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| /s/ Jun Ma . | |||
|
|
| Jun Ma | |
| President and Chief Executive Officer |
Date: August 15, 2022
EXHIBIT 31.2
CERTIFICATION PURSUANT TO RULE 13a/15d OF THE SECURITIES EXCHANGE ACT OF 1934,
AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Michael J. Beecher, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Vaso Corporation and subsidiaries (the “registrant”); |
|
|
|
| 2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
|
|
|
| 3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
|
|
|
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
|
| a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
|
|
|
|
|
| b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
|
|
|
|
|
| c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
|
|
|
|
|
| d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s Board of Directors (or persons performing the equivalent functions): |
|
| a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize, and report financial information; and |
|
|
|
|
|
| b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
| /s/ Michael J. Beecher . | |||
|
|
| Michael J. Beecher | |
| Chief Financial Officer | |||
Date: August 15, 2022
EXHIBIT 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Vaso Corporation and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jun Ma, as President and Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
|
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Jun Ma . | |||
|
|
| Jun Ma | |
| President and Chief Executive Officer | |||
Dated: August 15, 2022
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the quarterly report of Vaso Corporation and subsidiaries (the “Company”) on Form 10-Q for the period ending June 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael J. Beecher, as Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
|
| (1) | The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
|
|
|
|
|
| (2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
| /s/ Michael J. Beecher . | |||
|
|
| Michael J. Beecher | |
| Chief Financial Officer | |||
Dated: August 15, 2022